Rare disease drug shows promise in reducing infections
NCT ID NCT02231879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection severity. Results showed some participants did better on plerixafor, but others had drug failures, highlighting the need for more research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plerixafor (also known as Mozobil) and G-CSF (also known as Neupogen)
What this could lead to
If plerixafor works better than G-CSF, it could offer a new treatment option to reduce severe infections in people with WHIM syndrome.
What could go wrong
This is a small, early-stage trial with only 20 participants, so results may not apply to everyone. Some participants had drug failures on plerixafor, meaning it didn't work for them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States